Antibody constructs for MSLN and CD3

A bispecific antibody construct comprising a first binding domain which binds to human mesothelin (MSLN) on the surface of a target cell and a second binding domain which binds to human CD3 epsilon on the surface of a T cell, wherein the first binding domain comprises a VH region comprising CDR-H1, CDR-H2 and CDR-H3 and a VL region comprising CDR-L1, CDR-L2 and CDR-L3, wherein said CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 comprise the amino acid sequences selected from the group consisting of:

• a) the amino acid sequences of SEQ ID NO:
• 161 (CDR-H1), SEQ ID NO:
• 162 (CDR-H2), SEQ ID NO:
• 163 (CDR-H3), SEQ ID NO:
• 164 (CDR-L1), SEQ ID NO:
• 165 (CDR-L2), and SEQ ID NO:
• 166 (CDR-L3);
• b) the amino acid sequences of SEQ ID NO:
• 171 (CDR-H1), SEQ ID NO:
• 172 (CDR-H2), SEQ ID NO:
• 173 (CDR-H3), SEQ ID NO:
• 174 (CDR-L1), SEQ ID NO:
• 175 (CDR-L2), and SEQ ID NO:
• 176 (CDR-L3);
• c) the amino acid sequences of SEQ ID NO:
• 181 (CDR-H1), SEQ ID NO:
• 182 (CDR-H2), SEQ ID NO:
• 183 (CDR-H3), SEQ ID NO:
• 184 (CDR-L1), SEQ ID NO:
• 185 (CDR-L2), and SEQ ID NO:
• 186 (CDR-L3);
• d) the amino acid sequences of SEQ ID NO:
• 191 (CDR-H1), SEQ ID NO:
• 192 (CDR-H2), SEQ ID NO:
• 193 (CDR-H3), SEQ ID NO:
• 194 (CDR-L1), SEQ ID NO:
• 195 (CDR-L2), and SEQ ID NO:
• 196 (CDR-L3);
• and
• e) the amino acid sequences of SEQ ID NO:
• 201 (CDR-H1), SEQ ID NO:
• 202 (CDR-H2), SEQ ID NO:
• 203 (CDR-H3), SEQ ID NO:
• 204 (CDR-L1), SEQ ID NO:
• 205 (CDR-L2), and SEQ ID NO:
• 206 (CDR-L3), and
• wherein the second binding domain comprises a heavy chain variable (VH) region and a light chain variable (VL) region.